HighTower Advisors LLC Buys 2,060 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

HighTower Advisors LLC grew its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 37.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 7,594 shares of the specialty pharmaceutical company’s stock after purchasing an additional 2,060 shares during the period. HighTower Advisors LLC’s holdings in Jazz Pharmaceuticals were worth $851,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in JAZZ. Rubric Capital Management LP acquired a new position in Jazz Pharmaceuticals during the 2nd quarter worth approximately $65,812,000. Pacer Advisors Inc. raised its position in shares of Jazz Pharmaceuticals by 40.7% during the second quarter. Pacer Advisors Inc. now owns 1,820,913 shares of the specialty pharmaceutical company’s stock worth $194,346,000 after purchasing an additional 527,187 shares during the period. Baupost Group LLC MA lifted its holdings in shares of Jazz Pharmaceuticals by 52.8% in the 2nd quarter. Baupost Group LLC MA now owns 1,274,248 shares of the specialty pharmaceutical company’s stock worth $136,000,000 after purchasing an additional 440,552 shares in the last quarter. Millennium Management LLC grew its position in Jazz Pharmaceuticals by 1,808.4% in the 2nd quarter. Millennium Management LLC now owns 450,872 shares of the specialty pharmaceutical company’s stock valued at $48,122,000 after purchasing an additional 427,246 shares during the period. Finally, Dimensional Fund Advisors LP increased its stake in Jazz Pharmaceuticals by 48.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,222,198 shares of the specialty pharmaceutical company’s stock valued at $130,447,000 after purchasing an additional 398,549 shares in the last quarter. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

JAZZ has been the topic of a number of recent research reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $140.00 price objective on shares of Jazz Pharmaceuticals in a research note on Monday, September 9th. Needham & Company LLC reaffirmed a “buy” rating and issued a $207.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, December 12th. Morgan Stanley raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $140.00 to $175.00 in a report on Thursday, December 12th. Royal Bank of Canada restated an “outperform” rating and issued a $179.00 target price on shares of Jazz Pharmaceuticals in a report on Tuesday, December 10th. Finally, Piper Sandler reissued an “overweight” rating and issued a $163.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, December 12th. Two analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $177.00.

Insider Activity

In related news, EVP Neena M. Patil sold 3,700 shares of the company’s stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $123.41, for a total value of $456,617.00. Following the transaction, the executive vice president now owns 33,048 shares in the company, valued at approximately $4,078,453.68. This represents a 10.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Bruce C. Cozadd sold 2,000 shares of the firm’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $121.17, for a total value of $242,340.00. Following the completion of the sale, the chief executive officer now directly owns 427,025 shares of the company’s stock, valued at $51,742,619.25. This represents a 0.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 6,753 shares of company stock valued at $816,289 in the last three months. Company insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Price Performance

JAZZ opened at $121.74 on Thursday. Jazz Pharmaceuticals plc has a fifty-two week low of $99.06 and a fifty-two week high of $134.17. The firm has a 50-day moving average of $118.02 and a 200 day moving average of $112.48. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The firm has a market cap of $7.36 billion, a P/E ratio of 17.15, a PEG ratio of 1.02 and a beta of 0.57.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.